Gemcitabine and pemetrexed (Alimta) in thoracic cancers: Present and future perspectives. Introduction and current controversies

Seminars in Oncology

Volumn 29, Issue 3 SUPPL. 9, 2002, Pages 43-46

  Le Chevalier, Thierry ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; GEMCITABINE; IRINOTECAN; PACLITAXEL; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CIGARETTE SMOKING; CONFERENCE PAPER; DRUG EFFICACY; EARLY DIAGNOSIS; FEMALE; FUTUROLOGY; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; THORAX TUMOR;

EID: 0036317531     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/sonc.2002.34272     Document Type: Conference Paper

References (20)

1. Global cancer statistics
2. Cancer surveillance series: Changing geographic patterns of lung cancer mortality in the United States, 1950 through 1994
3. Cancer mortality in Europe, 1990-1994, and an overview of trends from 1955 to 1994
4. Cancer statistics, 2000
5. Randomized trial of chemoprevention with vitamin A and N-acetylcysteine in patients with cancer of the upper and lower airways: The Euroscan study
6. Effect of tobacco smoking on various histilogical types of lung cancer
7. Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials
8. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small cell lung cancer. A Southwest Oncology Group trial
9. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer
10. A randomized trial of the four most active regimens for metastatic non-small cell lung cancer
11. Chemotherapy of non-small cell lung cancer: A comparison of three active regimens. A randomised trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.)
12. GEMZAR vs. GEMZAR + carboplatin in advanced NSCLC: A phase III randomized trial of the Swedish Lung Cancer Study Group
13. Phase I-II and pharmacokinetic study combining gemcitabine (GEM) with oxaliplatin (OX) in patients (pts) with advanced non-small cell lung (NSCLC) and ovarian carcinoma (OC)
14. Phase III trial of neo-adjuvant chemotherapy (NCT) in resectable stage I (except T1NO), II, IIIa non-small cell lung cancer (NSCLC): The French experience
15. Activity of the multi-targeted antifolate MTA (LY 231514) in advanced non-small cell lung cancer (NSCLC)
16. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: A phase II study
17. Phase II trial of MTA (LY 231514) in patients with non-small cell lung cancer who relapsed after previous platinum or non-platinum chemotherapy
18. Frontline treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: A multicenter phase II trial
19. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: A study of the National Cancer Institute of Canada Clinical Trials Group